Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for Nivolumab (BMS-936558)

8 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Treatment

    ECOGHEME4412

    08/18/2016

    A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma

    Treatment

    VICCTHO1625

    06/01/2016

    An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as First Line-Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC)

    Treatment

    ECOGMELEA6141

    05/10/2016

    Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

    Treatment

    VICCTHO1595

    03/25/2016

    An Open-label, Randomized, Phase 3 Study of Nivolumab or Chemotherapy in Subjects with Relapsed Small-cell Lung Cancer after Platinum-based First Line Chemotherapy

    Treatment

    VICCPHI1531

    03/01/2016

    A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers

    Treatment

    VICCTHO1573

    02/01/2016

    An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus platinum doublet chemotherapy versus platinum doublet chemotherapy in Subjects with Chemotherapy-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)

    Treatment

    ECOGTHOS1400

    04/02/2015

    Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer

    Treatment

    VICCHEM13105

    04/09/2014

    A Single-Arm, Open-Label Phase 2 Study of Nivolumab (BMS-936558) in Subjects with Relapsed or Refractory Follicular Lymphoma (FL)


    Print this page for your doctor